Trial Profile
An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2023
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms THoMAS
- 29 Mar 2023 Planned End Date changed from 30 Oct 2023 to 30 Jul 2023.
- 21 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2021 Planned End Date changed from 30 May 2022 to 30 Oct 2023.